X-Zell
X-Zell, a healthcare diagnostics company launched in 2014, specializes in rare cell detection technology and operates in Singapore, Thailand, and Germany. The company offers early, pain-free cancer detection and same-day diagnostics through its innovative platform technology.
Company Overview
X-Zell is a healthcare company specializing in diagnostics. Established in November 2014, the company focuses on rare cell detection technology, offering early and pain-free cancer detection. X-Zell has operations across various regions, including Singapore, Thailand, Germany, Southeast Asia, and Europe. The company employs a team of 19 members and participated in Y Combinator's W15 batch. It aims to revolutionize cytopathology to maximize data output, reduce turnaround time, and make minimally invasive diagnostics accessible.
Locations
X-Zell operates from three primary locations: Singapore; Bangkok, Thailand; and Düsseldorf, Germany. These locations enable the company to serve clients across Southeast Asia and Europe, ensuring robust results and maximum clinical utility in a broad range of medical applications. X-Zell offers both remote and partly remote services, further extending their reach and enabling flexibility in diagnostics delivery.
Technology and Innovations
X-Zell has developed advanced platform technology capable of isolating and visualizing rare and abnormal cells, such as Circulating Endothelial Cells (CEC). This technology is built on four core modules that cover the entire spectrum from blood processing to cell analysis and reporting. Their system fuses multi-channel immunostaining with digital single-cell imaging to enable same-day cancer diagnosis from minimally invasive body liquids. Innovations like direct-to-slide sample fixation, simultaneous eight-channel immunostaining without cytoblocking, and instant on-screen analysis reduce the sample-to-diagnosis time significantly.
Collaborations
X-Zell collaborates with leading medical institutions to advance its diagnostic technologies. In 2023, MVZ Frankfurt, a renowned cytopathology center in Germany, introduced Cryoimmunostaining™ developed by X-Zell as a routine method for analyzing pleural effusion and ascites fluid. This collaboration highlights X-Zell's commitment to improving diagnostic techniques and expanding the clinical utility of its technologies.
Y Combinator and Investor Backing
X-Zell is backed by Y Combinator, having participated in its W15 batch, and several high-profile angel investors. Being part of Y Combinator's network has provided X-Zell with valuable resources and mentorship, fueling its innovation and growth in the healthcare diagnostics industry. This support has enabled X-Zell to establish itself as a recognized and awarded entity in medical technology and diagnostics.